Patents
Sitemap › C07 - Organic chemistry › C07K - Peptides › C07K 7 - Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
Patents for C07K 7 - Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof (42,273)
09/2005
09/21/2005EP1575524A2 Proliferated cell lines and uses thereof
09/21/2005EP1575511A2 A new target for angiogenesis and anti-angiogenesis therapy
09/21/2005EP1575496A2 Colon tumor specific binding peptides
09/21/2005EP1404377B1 Improved chelator conjugates
09/21/2005EP0793721B1 Peptides capable of binding to the gap protein sh3 domain, nucleotide sequences coding therefor, and preparation and use thereof
09/21/2005CN1672052A Nano-sized optical fluorescence labels and uses thereof
09/21/2005CN1671859A Method for identifying individual active entities from complex mixtures
09/21/2005CN1671840A Novel enzyme forming peptide, microorganism producing the same and process for producing dipeptide using them
09/21/2005CN1671395A Process for preparing water soluble phosphonooxymethyl derivatives of alcohol and phenol
09/21/2005CN1219794C Platelet glucoprotein receptor inhibitor, medicinal composition containing same and use thereof
09/20/2005US6946480 Glutaminyl based DPIV inhibitors
09/15/2005WO2005085288A2 Natural igm antibodies and inhibitors thereof
09/15/2005WO2005085282A1 Il-15 binding site for il15-ralpha and specific il-15 mutants having agonists/antagonists activity
09/15/2005WO2005085277A1 Cyclic hexapeptides, process and use thereof
09/15/2005WO2005085276A1 A novel potassium channel modulator peptide
09/15/2005WO2005085197A1 Cyclobutenedione groups-containing compounds as inhibitors of hepatitis c virus ns3 serine protease
09/15/2005WO2005084694A1 Influenza virus-infection inhibitor
09/15/2005WO2005084266A2 Functional method for generating or screening for ligands which modulate steroid hormone receptors
09/15/2005WO2005047316A3 Insulin releasing peptides
09/15/2005WO2005040802A3 Cylin binding peptides, and their use in drug screening assays
09/15/2005WO2005026323A3 Stationary phases and a purification process using the stationary phases
09/15/2005WO2005016232A3 Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
09/15/2005WO2004094461A3 Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
09/15/2005WO2004085461A3 Tumour-associated peptides binding to mhc molecules
09/15/2005WO2004047771A3 Peptides which inhibit angiogenesis, cell migration, cell invasion and cell proliferation, compositions and uses thereof
09/15/2005US20050203288 Amino acid sequences which suppress the activities of inhibitors of apoptosis proteins (IAPs); for use as tool in treatment of cell proliferative disorders
09/15/2005US20050203028 Method of preparing peptide
09/15/2005US20050203027 Reduced toxicity, improved specificity for targeted protease
09/15/2005US20050203026 Rosacea; vascular endothelial growth factor inhibitors; protease inhibitors such as Bowman-Birk Inhibitor, soybean trypsin inhibitor, and Eglin chymotrypsin inhibitor
09/15/2005US20050203025 Compounds and methods for modulating nonclassical cadherin-mediated functions
09/15/2005US20050203024 Peptides and methods for inducing cellular resistance to infection
09/15/2005US20050203016 Method of drug delivery through selective targeting, of biological tissues containing populations of receptor proteins, with novel conjugate molecules
09/15/2005US20050203006 Novel lipopeptides as antibacterial agents
09/15/2005US20050203005 Peptide structure containing lanthionine and methyllanthionine as constituents isolated from Microbispora sp. ATCC PTA-5024; methicillin resistant and vancomycin resistant bacteria; M. catharralis, Neisseria species and H. influenzae and Mycobacteria
09/15/2005US20050203003 Contulakin-G, analogs thereof and uses therefor
09/15/2005US20050202535 Fusion protein comprising bowman-kirk, soybean trypsin and eglin C inhibitors for use in treatment and prevention of inflammatory, arthritic and skin disorders
09/15/2005US20050202532 Amino acid sequences for prevention and treatment of cardiovascular disease
09/15/2005US20050202515 Using vitamin d3 receptor (VDR) and modulator of non-genomic activity of nuclear receptors (MNAR) as tools in identifying compounds for prevention and treatment of cell proliferative and bone disorders
09/15/2005US20050202034 polypeptide relating to the autoimmune disease pemphigus vulgaris
09/15/2005US20050202033 Heat shock protein-based vaccines and immunotherapies
09/15/2005US20050202027 Multivalent compounds for crosslinking receptors and uses thereof
09/15/2005US20050201939 Dye-peptide complex; supplying to tumor cells; for diagnostic imaging and therapy; biocompatibility
09/15/2005US20050201934 Binding peptides for carcinoembryonic antigen (CEA)
09/15/2005US20050201932 Drug delivery using Polymeric immunoglobulin receptor (pIgR) which when cleaved has a stalk region which remains attached to the cell and a secretory component (SC) which exists in an organ of interest in several forms
09/15/2005DE102004011503A1 Identifying and quantifying tumor-associated peptides by chemically identically modifying peptides to generate different physical characteristics, useful for treating tumorous and/or adenomatous diseases
09/15/2005CA2812132A1 Natural igm antibodies and inhibitors thereof
09/15/2005CA2560066A1 Natural igm antibodies and inhibitors thereof
09/15/2005CA2559067A1 Influenza virus infection suppressor
09/15/2005CA2558664A1 Functional method for generating or screening for ligands which modulate steroid hormone receptors
09/15/2005CA2557301A1 Cyclobutenedione groups-containing compounds as inhibitors of hepatitis c virus ns3 serine protease
09/14/2005EP1574507A2 Furo- and pyrano-naphthoquinones and their use in the treatment of cancer
09/14/2005EP1574219A2 Method of inhibiting fibrosis with a somatostatin agonist
09/14/2005EP1573323A2 Prion protein ligands and methods of use
09/14/2005EP1573025A2 Crystallized structure of type iv collagen nc1 domain hexamer
09/14/2005EP1573023A2 Nucleic acid and corresponding protein entitled 162p1e6 useful in treatment and detection of cancer
09/14/2005EP1572966A2 Complete biosynthetic gene set for synthesis of polyketide antibiotics, including the albicidin family, resistance genes and uses thereof
09/14/2005EP1572892A2 Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
09/14/2005EP1572863A2 Method for identifying inhibitors of g protein coupled receptor signaling
09/14/2005EP1572743A2 Peptides and their use for the treatment of hiv infections
09/14/2005EP1572727A1 On-growth inhibiting compounds
09/14/2005EP1572726A2 4-methylhexanoic kahalalide f compound
09/14/2005EP1572725A1 Novel chi-conotoxin peptides (-i)
09/14/2005EP1572724A2 Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy
09/14/2005EP1572723A2 Skin or hair binding peptides
09/14/2005EP1572720A2 Method for enzymatic production of glp-2(1-33) and glp-2-(1-34) peptides
09/14/2005EP1572719A2 Partial peptide mimetics and methods
09/14/2005EP1572363A2 High capacity methods for separation, purification, concentration, immobilization and synthesis of compounds and applications based thereupon
09/14/2005EP1572224A2 Methods and compositions for inhibiting binding of ige to a high affinity receptor
09/14/2005EP1572168A2 Anti-infarction molecules
09/14/2005EP1572149A2 Immunogenicity of glucan binding protein
09/14/2005EP1572121A2 Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
09/14/2005EP1572090A2 Cancer vaccine containing cross-species epitopes of telomerase reverse transcriptase
09/14/2005EP1572076A2 Helical peptidomimetics
09/14/2005EP1572066A2 Novel method and composition for inhibition of angiogenesis and tumor growth using compounds based on a sequence within mmp-2
09/14/2005EP1571909A2 Optimized multi-epitope constructs and uses thereof
09/14/2005EP1224270B1 Mimic cellulose binding domain
09/14/2005CN1668335A Drug pre-targeting by means of bi-specific antibodies and hapten constructs comprising a carrier peptide and the active agent(s)
09/14/2005CN1218958C Novel cyclosporin with improved activity profile
09/13/2005US6943233 Cyclic peptides and aids vaccines
09/13/2005US6943147 Cancer treatment using proANP peptides
09/13/2005US6942987 Methods for measuring kinase activity
09/13/2005US6942985 Diagnosisng colon or rectal cancer in mammals; obtain tissue sample, detect concentration of preferential receptor protein, amplified concentration of protein indicates cancer
09/13/2005US6942963 measuring cytoxicity; drug screening
09/13/2005CA2335394C Aerothricin analogs, their preparation and use
09/12/2005CA2458084A1 Novel process for octreotide synthesis
09/09/2005WO2005083074A1 Tumor antigen peptides
09/09/2005WO2005082927A2 Antihypertensive peptides
09/09/2005WO2005082394A1 Phosphorylation inhibitors for insulin receptor
09/09/2005WO2005082348A2 Inhibitors of dipeptidylpeptidase iv for regulating glucose metabolism
09/09/2005WO2005030797A3 Melanocortin receptor agonists
09/09/2005WO2003086284A3 Colon tumor specific binding peptides
09/09/2005CA2558155A1 Casein derived peptides and therapeutic uses thereof
09/09/2005CA2558106A1 Inhibitors of dipeptidylpeptidase iv for regulating glucose metabolism
09/09/2005CA2556893A1 Antihypertensive peptides
09/09/2005CA2556830A1 Methods and compositions comprising non-peptide small molecules that solubilize beta amyloid peptide fiber
09/09/2005CA2556479A1 Methods and compositions comprising supramolecular constructs
09/09/2005CA2556022A1 Protein phosphorylation in t-cell receptor signaling pathways
09/09/2005CA2556021A1 Protein phosphorylation in anaplastic large cell lymphoma
09/09/2005CA2556019A1 Protein phosphorylation in c-src signaling pathways
09/08/2005US20050197299 Peptidomimetic protease inhibitors
1 ... 201 202 203 204 205 206 207 208 209 210 211 212 213 214 215 216 217 218 219 220 221 ... 423